On the behavioural specificity of hypophagia induced in male rats by mCPP, naltrexone, and their combination.

F L Wright, R J Rodgers
Author Information
  1. F L Wright: Behavioural Neuroscience Laboratory, Institute of Psychological Sciences, University of Leeds, Leeds, LS2 9JT, UK.

Abstract

RATIONALE: Serotonergic (5-hydroxytryptamine, 5-HT) and opioidergic mechanisms are intimately involved in appetite regulation.
OBJECTIVES: In view of recent evidence of positive anorectic interactions between opioid and various non-opioid substrates, our aim was to assess the behavioural specificity of anorectic responses to the opioid receptor antagonist naltrexone, the 5-HT2C/1B receptor agonist mCPP and their combination.
METHODS: Behavioural profiling techniques, including the behavioural satiety sequence (BSS), were used to examine acute drug effects in non-deprived male rats tested with palatable mash. Experiment 1 characterised the dose-response profile of mCPP (0.1-3.0 mg/kg), while experiment 2 assessed the effects of combined treatment with a sub-anorectic dose of mCPP (0.1 mg/kg) and one of two low doses of naltrexone (0.1 and 1.0 mg/kg).
RESULTS: Experiment 1 confirmed the dose-dependent anorectic efficacy of mCPP, with robust effects on intake and feeding-related measures observed at 3.0 mg/kg. However, that dose was also associated with other behavioural alterations including increased grooming, reductions in locomotion and sniffing, and disruption of the BSS. In experiment 2, naltrexone dose-dependently reduced food intake and time spent feeding, effects accompanied by a behaviourally selective acceleration in the BSS. However, the addition of 0.1 mg/kg mCPP did not significantly alter the behavioural changes observed in response to either dose of naltrexone given alone.
CONCLUSIONS: In contrast to recently reported positive anorectic interactions involving low-dose combinations of opioid receptor antagonists or mCPP with cannabinoid CB1 receptor antagonists, present results would not appear to provide any support for potentially clinically relevant anorectic interactions between opioid and 5-HT2C/1B receptor mechanisms.

References

  1. Psychopharmacology (Berl). 2000 Oct;152(3):256-67 [PMID: 11105935]
  2. Pharmacol Biochem Behav. 1987 Mar;26(3):515-20 [PMID: 3575366]
  3. Eur J Pharmacol. 2000 Jan 10;387(2):197-204 [PMID: 10650160]
  4. Psychopharmacology (Berl). 2013 Apr;226(3):475-90 [PMID: 23184281]
  5. Physiol Behav. 2003 Jul;79(2):227-38 [PMID: 12834794]
  6. Eur J Pharmacol. 1989 May 30;164(3):445-54 [PMID: 2767117]
  7. Science. 2002 Jul 26;297(5581):609-11 [PMID: 12142539]
  8. Metabolism. 2001 Aug;50(8):889-93 [PMID: 11474475]
  9. Psychopharmacology (Berl). 1994 Jan;113(3-4):369-77 [PMID: 7862847]
  10. J Physiol Pharmacol. 2007 Jun;58(2):349-60 [PMID: 17622702]
  11. Neuropharmacology. 2012 Jul;63(1):31-45 [PMID: 22491021]
  12. Psychopharmacology (Berl). 1991;105(4):467-76 [PMID: 1771214]
  13. Brain Res Bull. 1986 Nov;17(5):615-9 [PMID: 3801925]
  14. Dis Model Mech. 2012 Sep;5(5):621-6 [PMID: 22915024]
  15. Eur J Pharmacol. 1987 Sep 23;141(3):429-35 [PMID: 3666036]
  16. Physiol Behav. 2009 Apr 20;97(1):125-30 [PMID: 19419667]
  17. Psychopharmacology (Berl). 2004 Oct;176(1):39-49 [PMID: 15138762]
  18. Pharmacol Biochem Behav. 2009 Jan;91(3):358-66 [PMID: 18755211]
  19. Neuroreport. 1991 Oct;2(10):627-9 [PMID: 1756245]
  20. Br J Pharmacol. 2011 Oct;164(4):1248-62 [PMID: 21265828]
  21. Physiol Behav. 2008 Jun 9;94(3):422-31 [PMID: 18394662]
  22. Int J Obes (Lond). 2008 Aug;32(8):1201-10 [PMID: 18560368]
  23. J Physiol Pharmacol. 2011 Aug;62(4):395-402 [PMID: 22100840]
  24. Eur J Pharmacol. 2002 May 10;442(3):237-9 [PMID: 12065077]
  25. Pharmacol Biochem Behav. 2010 Nov;97(1):3-14 [PMID: 20214921]
  26. Eur J Neurosci. 2007 May;25(10):3115-24 [PMID: 17561825]
  27. Obesity (Silver Spring). 2009 Jan;17(1):30-9 [PMID: 18997675]
  28. Pharmacol Biochem Behav. 1991 Mar;38(3):605-10 [PMID: 1906186]
  29. Physiol Behav. 1998 Jun 15;64(4):557-61 [PMID: 9761232]
  30. Psychopharmacology (Berl). 1988;96(1):93-100 [PMID: 2906446]
  31. Brain Res. 2010 Sep 2;1350:86-94 [PMID: 20096672]
  32. Eur J Neurosci. 2001 Apr;13(7):1444-52 [PMID: 11298806]
  33. Eur J Pharmacol. 1992 Dec 8;229(1):9-14 [PMID: 1473565]
  34. Clin Pharmacol Ther. 1992 May;51(5):586-94 [PMID: 1587072]
  35. Brain Res. 2010 Sep 2;1350:43-64 [PMID: 20388498]
  36. Psychopharmacology (Berl). 2001 Jan 1;153(2):267-70 [PMID: 11205430]
  37. Endocrinology. 2005 Sep;146(9):3748-56 [PMID: 15932924]
  38. Physiol Behav. 2003 Oct;80(1):37-47 [PMID: 14568306]
  39. Am J Clin Nutr. 2012 Feb;95(2):297-308 [PMID: 22158731]
  40. J Psychopharmacol. 1993 Jan;7(3):257-64 [PMID: 22290839]
  41. Endocrinology. 2007 Dec;148(12):6054-61 [PMID: 17761760]
  42. Trends Neurosci. 2013 Feb;36(2):133-40 [PMID: 23312373]
  43. Neuropharmacology. 1999 Aug;38(8):1083-152 [PMID: 10462127]
  44. Pharmacol Biochem Behav. 2010 Nov;97(1):63-83 [PMID: 20688100]
  45. Obesity (Silver Spring). 2012 Jul;20(7):1426-36 [PMID: 22421927]
  46. Drugs. 2007;67(1):27-55 [PMID: 17209663]
  47. Pharmacol Biochem Behav. 1988 Feb;29(2):387-92 [PMID: 3283779]
  48. J Pharmacol Exp Ther. 2008 May;325(2):567-76 [PMID: 18256173]
  49. Eur J Pharmacol. 1995 Mar 14;275(3):301-5 [PMID: 7768299]
  50. Neuron. 2006 Jul 20;51(2):239-49 [PMID: 16846858]
  51. Pharmacol Biochem Behav. 1986 Jul;25(1):123-8 [PMID: 3749218]
  52. Neuropharmacology. 2012 Jul;63(1):132-46 [PMID: 22313529]
  53. Annu Rev Neurosci. 1984;7:309-38 [PMID: 6143527]
  54. Behav Pharmacol. 1992 Dec;3(6):621-634 [PMID: 11224163]
  55. J Clin Psychiatry. 2007 Aug;68(8):1226-9 [PMID: 17854247]
  56. Brain Res Bull. 1990 Dec;25(6):953-60 [PMID: 2149668]
  57. Obesity (Silver Spring). 2011 Jan;19(1):121-7 [PMID: 20559304]
  58. Int J Neuropsychopharmacol. 2009 Aug;12(7):995-1008 [PMID: 19433009]
  59. Psychopharmacology (Berl). 1994 Sep;116(1):120-2 [PMID: 7862925]
  60. Obesity (Silver Spring). 2009 Sep;17(9):1736-43 [PMID: 19521351]
  61. Psychopharmacology (Berl). 2001 Dec;159(1):111-6 [PMID: 11797078]
  62. Physiol Behav. 2004 Mar;81(1):129-40 [PMID: 15059692]
  63. Behav Brain Res. 2010 Feb 11;207(1):174-81 [PMID: 19818809]
  64. Pharmacol Biochem Behav. 1997 Dec;58(4):1103-7 [PMID: 9408220]
  65. Psychopharmacology (Berl). 1997 Oct;133(3):309-12 [PMID: 9361339]
  66. Life Sci. 1990;47(3):195-203 [PMID: 1975081]
  67. Appetite. 1984 Mar;5(1):45-52 [PMID: 6486777]
  68. Neuropsychopharmacology. 2012 Apr;37(5):1177-91 [PMID: 22189292]
  69. Naunyn Schmiedebergs Arch Pharmacol. 1979 Aug;308(2):159-63 [PMID: 503247]
  70. Nat Chem Biol. 2009 Oct;5(10):749-57 [PMID: 19597507]
  71. Neuropharmacology. 2012 Jul;63(1):3-17 [PMID: 22313528]
  72. Behav Brain Res. 2008 Mar 5;187(2):417-27 [PMID: 18022706]
  73. Proc Natl Acad Sci U S A. 2008 May 20;105(20):7257-62 [PMID: 18458326]
  74. Nat Rev Endocrinol. 2010 May;6(5):255-69 [PMID: 20234354]
  75. Obes Res. 1995 Nov;3 Suppl 4:449S-462S [PMID: 8697043]
  76. Neuropharmacology. 2012 Jul;63(1):124-31 [PMID: 22710443]
  77. Expert Opin Pharmacother. 2009 Apr;10(6):921-5 [PMID: 19351275]
  78. Pharmacol Biochem Behav. 1989 May;33(1):17-20 [PMID: 2780774]
  79. Psychopharmacology (Berl). 2013 Jul;228(2):291-307 [PMID: 23455599]
  80. Ann N Y Acad Sci. 2003 Jun;994:169-74 [PMID: 12851313]
  81. Br J Pharmacol. 1988 May;94(1):137-47 [PMID: 3401632]
  82. Curr Opin Investig Drugs. 2009 Oct;10(10):1117-25 [PMID: 19777400]
  83. Physiol Behav. 2009 Jul 14;97(5):537-50 [PMID: 19336238]
  84. Pharmacol Rev. 1994 Jun;46(2):157-203 [PMID: 7938165]
  85. Peptides. 2004 Apr;25(4):697-725 [PMID: 15165728]
  86. Neuropsychopharmacology. 2012 Nov;37(12):2643-52 [PMID: 22805601]
  87. Am J Physiol Regul Integr Comp Physiol. 2010 Sep;299(3):R945-52 [PMID: 20554932]
  88. Pharmacol Biochem Behav. 2002 Apr;71(4):691-700 [PMID: 11888560]
  89. Pharmacol Biochem Behav. 1998 Oct;61(2):159-68 [PMID: 9738531]

MeSH Term

Animals
Body Weight
Dose-Response Relationship, Drug
Eating
Feeding Behavior
Grooming
Habituation, Psychophysiologic
Male
Motor Activity
Naltrexone
Narcotic Antagonists
Piperazines
Rats
Satiety Response
Serotonin 5-HT1 Receptor Agonists
Serotonin 5-HT2 Receptor Agonists
Time Factors

Chemicals

Narcotic Antagonists
Piperazines
Serotonin 5-HT1 Receptor Agonists
Serotonin 5-HT2 Receptor Agonists
Naltrexone
1-(3-chlorophenyl)piperazine

Word Cloud

Created with Highcharts 10.0.0mCPP01anorecticbehaviouralreceptornaltrexonemg/kgopioideffectsinteractionsBSSdosemechanismspositivespecificity5-HT2C/1BcombinationincludingmaleratsExperimentexperiment2intakeobservedHoweverantagonistsRATIONALE:Serotonergic5-hydroxytryptamine5-HTopioidergicintimatelyinvolvedappetiteregulationOBJECTIVES:viewrecentevidencevariousnon-opioidsubstratesaimassessresponsesantagonistagonistMETHODS:Behaviouralprofilingtechniquessatietysequenceusedexamineacutedrugnon-deprivedtestedpalatablemashcharacteriseddose-responseprofile1-3assessedcombinedtreatmentsub-anorecticonetwolowdosesRESULTS:confirmeddose-dependentefficacyrobustfeeding-relatedmeasures3alsoassociatedalterationsincreasedgroomingreductionslocomotionsniffingdisruptiondose-dependentlyreducedfoodtimespentfeedingaccompaniedbehaviourallyselectiveaccelerationadditionsignificantlyalterchangesresponseeithergivenaloneCONCLUSIONS:contrastrecentlyreportedinvolvinglow-dosecombinationscannabinoidCB1presentresultsappearprovidesupportpotentiallyclinicallyrelevanthypophagiainduced

Similar Articles

Cited By